Creative Medical Technology Holdings Inc (CELZ) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Creative Medical Technology Holdings Inc stock $0.80, price $0.62, upside +28.5%, quality 32 out of 100. Rating: undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range $0.6060 – $174.50 · fair‑value band $0.5270 – $0.9945 · the $0.6220 price screens below the $0.7990 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Creative Medical Technology Holdings in your weekly email
Every Wednesday you see whether Creative Medical Technology Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.
Show moreShow less
The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness.
It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment.
In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Stock analysis
Creative Medical Technology Holdings Inc (CELZ) currently trades at $0.6220, while our model-based Fair Value estimate is $0.7990, implying the stock looks roughly 22% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.5270 (bear) to $0.9945 (bull), the price of $0.6220 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2021: revenue and profit before it include the divested business. Growth is measured afresh from 2021.
Creative Medical Technology Holdings Inc reported revenue of $6.0K in FY2025 versus $87.8K in FY2021, a compound −48.9%/yr. Reported net income was −$6.0M in FY2025.
Our AI-assisted moat analysis scores the competitive advantage at 2 out of 100 (medium confidence).
What moves the price
The share trades about 81% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 28%, CELZ screens cheaper than that median.
Fair Value models
Bear$0.5270Fair Value $0.7990Bull$0.9945
Price $0.6220 · Upside +28.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham)$0.6200$0.9400$1.1752
All 1 models by family
Asset-Based
NCAV (Graham)$0.6200$0.9400$1.1752
The fair value above starts from this blend and is adjusted for dilution from new shares.
In the last 6 months, no officer or director bought or sold shares on the open market.
Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2021: revenue and profit before it include the divested business. Growth is measured afresh from 2021.
Revenue growth 1 year
−45.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−59.2%
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−677.7% (2020) → −102,380.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Creative Medical Technology Holdings Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 3/5 measures
Overall it ranks above its industry peers.
Valuation
Quality Score32 · Bottom 25%
Fair Value upside+28.5% · Top 25%
Profitability
Return on assets−76.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)0.0% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Creative Medical Technology Holdings Inc Fair Value". https://www.fairvalue-calculator.com/stock/CELZ
Frequently asked questions
Is Creative Medical Technology Holdings Inc (CELZ) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of $0.7990 versus a price of $0.6220, about +28% upside (undervalued).
What is the fair value of CELZ?
Our model-based fair value for Creative Medical Technology Holdings Inc is $0.7990 (as of Nov 9, 2026), built from audited fundamentals. The current price: $0.6220.
What is the quality score of CELZ?
Creative Medical Technology Holdings Inc has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Creative Medical Technology Holdings Inc (CELZ)?
Our model-based price target is the fair value of $0.7990 (as of Nov 9, 2026) from 1 valuation models. Cautious scenario $0.5270, optimistic scenario $0.9945. It is a calculation from audited fundamentals, not an analyst target.
What is the Creative Medical Technology Holdings Inc stock forecast for 2026?
Our models put fair value at $0.7990, about +28% upside versus a price of $0.6220 (undervalued). Cautious scenario $0.5270, optimistic scenario $0.9945. The calculation is refreshed regularly with new filings.
What is the revenue of Creative Medical Technology Holdings Inc (CELZ)?
Creative Medical Technology Holdings Inc reported trailing-twelve-month revenue of about $3.0K (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Creative Medical Technology Holdings Inc (CELZ)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Creative Medical Technology Holdings Inc it is $0.7990 per share (as of Nov 9, 2026), against a price of $0.6220. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Creative Medical Technology Holdings Inc stock overvalued or undervalued in 2026?
As of Nov 9, 2026, CELZ trades below its calculated fair value: price $0.6220, fair value $0.7990, a gap of about +28% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CELZ?
No. The price is what the market pays today ($0.6220); the fair value is what the company's own numbers justify ($0.7990). For Creative Medical Technology Holdings Inc the two are $0.1770 per share apart. That gap is exactly why we show both numbers side by side.
How much is Creative Medical Technology Holdings Inc worth?
The market values Creative Medical Technology Holdings Inc at about $4.7M (market capitalisation, as of Nov 9, 2026). Per share that is $0.6220; our models calculate a fair value of $0.7990 per share.
What do the bullish and bearish scenarios say about CELZ?
Our models span a range for Creative Medical Technology Holdings Inc: cautious scenario $0.5270, base $0.7990, optimistic $0.9945 per share (as of Nov 9, 2026, price $0.6220). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Creative Medical Technology Holdings Inc (CELZ)?
Balance-sheet figures for Creative Medical Technology Holdings Inc (as of Nov 9, 2026): return on equity −77.9%. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is CELZ from its 52-week high?
Creative Medical Technology Holdings Inc trades at $0.6220, about 81% below its 52-week high of $3.28 and 3% above the low of $0.6060 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.7990 is for.
Which stocks are comparable to Creative Medical Technology Holdings Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Creative Medical Technology Holdings Inc stock attractive at the current price?
The data as of Nov 9, 2026: price $0.6220, calculated fair value $0.7990 (+28%), Quality Score 32/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CELZ calculated?
We run Creative Medical Technology Holdings Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.7990 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Creative Medical Technology Holdings Inc currently trades 22% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Creative Medical Technology Holdings Inc (CELZ)?
The closing price on Nov 6, 2026 was $0.6220. Our model-based fair value is $0.7990, about +28% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Creative Medical Technology Holdings Inc right now?
A fairly wide model range ($0.5270 to $0.9945) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Creative Medical Technology Holdings Inc
How large is the market capitalisation of Creative Medical Technology Holdings Inc (CELZ)?
The market capitalisation of Creative Medical Technology Holdings Inc is $4.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Creative Medical Technology Holdings Inc (CELZ)?
Earnings per share at Creative Medical Technology Holdings Inc are $−2.07. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Creative Medical Technology Holdings Inc (CELZ)?
The return on equity (ROE) of Creative Medical Technology Holdings Inc is −77.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Creative Medical Technology Holdings Inc (CELZ)?
On an EBIT basis the return on assets of Creative Medical Technology Holdings Inc is −59.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Creative Medical Technology Holdings Inc (CELZ)?
The operating margin of Creative Medical Technology Holdings Inc is −208,004% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast are earnings growing at Creative Medical Technology Holdings Inc (CELZ)?
Earnings per share at Creative Medical Technology Holdings Inc are growing +359% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Creative Medical Technology Holdings Inc (CELZ) generate?
The free cash flow of Creative Medical Technology Holdings Inc is −$5.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Creative Medical Technology Holdings Inc (CELZ) hold?
Creative Medical Technology Holdings Inc holds more cash than debt, $7.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Creative Medical Technology Holdings Inc in the live analysis
One click puts Creative Medical Technology Holdings Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026
